Format

Send to

Choose Destination
See comment in PubMed Commons below
J Popul Ther Clin Pharmacol. 2013;20(2):e161-2. Epub 2013 Jul 14.

The return to the USA of doxylamine-pyridoxine delayed release combination (Diclegis®) for morning sickness--a new morning for American women.

Author information

1
Motherisk Program, Department of Pediatrics, The Hospital for Sick Children, and the University of Toronto, Toronto, Canada. gkoren@sickkids.ca

Abstract

The US FDA approval in April 2013 of Diclegis®, the doxylamine-pyridoxine combination for morning sickness, is a major milestone, particularly since it is indicated for use in pregnancy and the FDA has labeled it a pregnancy category A drug the strongest evidence of fetal safety. After thirty years of being orphaned from an FDA-labeled drug for the most common medical condition in pregnancy, American women and their health care providers have a therapeutic solution that is likely to positively impact millions of women each year. This review highlights the milestones of this antiemetic agent over the last 40 years.

PMID:
23863487
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center